Risk-benefit ratio must be taken into accountBMJ 1996; 313 doi: https://doi.org/10.1136/bmj.313.7071.1553a (Published 14 December 1996) Cite this as: BMJ 1996;313:1553
- Stuart Dollow
- Senior medical adviser Medical Department, Roche Products, PO Box 8, Welwyn Garden City AL7 3AY
EDITOR,—P J Barrett and colleagues report that mefloquine is associated with an excess of neuropsychiatric adverse events compared with chloroquine plus proguanil (27.4% v 16.0%).1 While there are similarities in methodology between the authors' study and Steffen et al's larger study,2 there are crucial differences in assessment criteria. I propose that any differences in incidence reports are a function of the defining criteria and that this may account for the disparities in perceptions of the tolerability of mefloquine. Nevertheless, I wish to make …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial